Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide versus placebo as add‑on to intensified basal‑bolus insulin therapy in type 2 diabetes mellitus
2014-001969-27Phase 3Terminated
- Sponsor
- GSK
- Start
- Oct 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Albiglutide add-on with Placebo add-on (2 arms). Primary endpoint: Percentage of subjects with severe or documented symptomatic hypoglycemia. Started Oct 2014; status: terminated.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-001969-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001969-27.